RxDoctor Payments Data

John McNerney, MD

Gastroenterology · Tucson, AZNPI 1568469583

Payments from drug & device makers

$12,930in general payments, 2019–2025

Across 512 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Pfizer$833
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$718
  • Aimmune Therapeutics, Inc.$632
  • plus $5K from 31 others

What the payments were for

  • Food & beverage$12,875100%
  • Education$550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,930 in reported general payments places this provider in the 70th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$204,605
Medicare patients
922
Services billed
1,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab23$329,824
Mesalamine84$49,663
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates445$27,755
LinzessLinaclotide33$22,175
NexiumEsomeprazole Magnesium13$12,434
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl436$6,686
Dexlansoprazole DrDexlansoprazole15$6,454
Omeprazole346$5,202
Balsalazide Disodium52$5,097
Mesalamine ErMesalamine29$4,759
DexilantDexlansoprazole14$4,466
Mercaptopurine45$3,624
Pantoprazole Sodium282$2,874
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl142$2,155
Budesonide DrBudesonide37$1,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,114$22,17533 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$1,252$4,46614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →